Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Porter

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantationD L Porter, S M Luger, K M Duffy, et al.
Bone Marrow Transplantation|April 28, 2010
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimenA Nazha, R Cook, D T Vogl, et al.
Bone Marrow Transplantation|October 14, 2008
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin, D T Vogl, D L Porter, et al.
Bone Marrow Transplantation|May 26, 2010
Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHDA Rager, N Frey, S C Goldstein, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 20, 2015
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative DisorderM R Luskin, D S Heil, K S Tan, et al.
Blood|February 9, 2000
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusionsD L Porter, R H Collins, C Hardy, et al.
Bone Marrow Transplantation|March 15, 2005
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantationA W Loren, S M Luger, E A Stadtmauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Bone Marrow Transplantation|February 7, 2012
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCTR Tizon, N Frey, D F Heitjan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapyH C Moore, R Mick, L J Solin, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantationD L Porter, S M Luger, K M Duffy, et al.
Bone Marrow Transplantation|April 28, 2010
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimenA Nazha, R Cook, D T Vogl, et al.
Bone Marrow Transplantation|October 14, 2008
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myelomaR L Olin, D T Vogl, D L Porter, et al.
Bone Marrow Transplantation|May 26, 2010
Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHDA Rager, N Frey, S C Goldstein, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 20, 2015
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative DisorderM R Luskin, D S Heil, K S Tan, et al.
Blood|February 9, 2000
Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusionsD L Porter, R H Collins, C Hardy, et al.
Bone Marrow Transplantation|March 15, 2005
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantationA W Loren, S M Luger, E A Stadtmauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantationR H Collins, O Shpilberg, W R Drobyski, et al.
Bone Marrow Transplantation|February 7, 2012
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCTR Tizon, N Frey, D F Heitjan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapyH C Moore, R Mick, L J Solin, et al.
Pageof 6